Skip to main content

Advertisement

SpringerLink
Log in

Renal plasma clearance: A valuable marker in myelomatosis

  • Original Articles
  • Published:
Blut Aims and scope Submit manuscript

Summary

Forty-two consecutive patients with untreated myelomatosis (MM) formed the basis of settling the validity of measuring the renal plasma clearance (RPC), either indirectly using the serum creatinine or directly using the glomerular filtration rate (GFR) when studying anaemia, calcium metabolism, proteins in serum and urine, and prognosis. Patients without light chain excretion in the urine had a higher GFR (P<0.01) than patients with light chain excretion. The haemoglobin concentration (Hb) was strongly correlated (P<0.001) to both, serum creatinine and GFR. Patients with normal serum concentrations of the physiological immunoglobulins had higher Hb (P<0.01) than patients with reduced serum immunoglobulins. Patients with serum calcium >3.00 mmol/l had additional reduced GFR compared with the other myeloma patients. The serum parathyroid hormone was decreased (P<0.01) and inversely correlated to the GFR. Patients with increased serum creatinine, reduced GFR or with osteolytic bone lesions had a decreased survival rate. The study shows that the major factor in prediction of Hb and prognosis in patients with MM is the RPC expressed either as the serum creatinine or the GFR. In addition, the significant correlations between the GFR and the other variables in MM assessed the RPC to be a useful and valuable marker in studies of anaemia, protein and calcium metabolism and prognosis in MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36: 1192

    Google Scholar 

  2. Armstrong JB (1950). A study of renal function in patients with multiple myeloma. Am J Med Sci 219: 488

    Google Scholar 

  3. Birgens HS, Hansen OP, Henriksen JH, Wantzin P (1979) Quantitation of erythropoiesis in myelomatosis. Scand J Haematol 22: 357

    Google Scholar 

  4. Brodwall EK (1964) Renal extraction of PAH in renal disease. Scand J Clin Lab Invest 1: 12

    Google Scholar 

  5. Carbone PP, Kellerhouse LE, Gehan EA (1967) Plasmocytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med 42: 937

    Google Scholar 

  6. Christensen MS (1976) A sensitive radioimmunoassay of pathyroid hormone in human serum using a specific extraction procedure. Scand J Clin Lab Invest 36: 313

    Google Scholar 

  7. Dammaco F, Waldenström J (1968) Bence Jones proteinuria in benign monoclonal gammapathies. Acta Med Scand 184: 403

    Google Scholar 

  8. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL (1978) Renal function in patients with multiple myeloma. Medicine 57: 151

    Google Scholar 

  9. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842

    Google Scholar 

  10. Fondu P, Haagaa P, Halvorsen S (1978) The regulation of erythropoiesis in protein-energy malnutrition. Br J Haematol 38: 29

    Google Scholar 

  11. Forbus WD, Perzweig WA, Parfentjev IA, Burwell JC Jr (1935) Bence-Jones protein excretion and its effect upon the kidney. Bull John Hopkins Hosp 57: 47

    Google Scholar 

  12. Goldman R, Adams W, Lushinger EB (1952) Renal function in myelomatosis. J Lab Clin Med 40: 519

    Google Scholar 

  13. Hansen OP (1978) Bone marrow studies in myelomatosis. Scand J Haematol 21: 265

    Google Scholar 

  14. Hansen OP (1980) Anaemi ved myelomatose. Kliniske og eksperimentelle studier. Thesis FADL's Forlag A/S, Copenhagen, pp 5–14

    Google Scholar 

  15. Hansen OP, Christensen MS, Birgens HS, Wantzin PS (1981) Immunoreaktivt parathyroideahormon i serum ved myelomatose. Ugeskr Laeg 143: 1908

    Google Scholar 

  16. Hansen OP, Drivsholm Aa (1978) Interrelationships between blood volumes, venous haematocrit and renal failure in myelomatosis. Scand J Haematol 20: 461

    Google Scholar 

  17. Hansen OP, Drivsholm Aa, Hippe E (1977) Vitamin B12 metabolism in myelomatosis. Scand J Haematol 18: 395

    Google Scholar 

  18. Hansen OP, Drivsholm Aa, Hippe E, Quadros E, Linnell J (1978) Interrelationship between vitamin B12 and folic acid in myelomatosis: Cobalamin Coenzyme and tetrahydrofolic acid function. Scand J Haematol 20: 360

    Google Scholar 

  19. Hansen OP, Jessen B, Videbaek Aa (1973) Prognosis of myelomatosis on treatment with prednisone and cytostatics. Scand J Haematol 10: 282

    Google Scholar 

  20. Hansen OP, Thorling EB, Drivsholm Aa (1977) Serum erythropoietin in myelomatosis. Scand J Haematol 19: 106

    Google Scholar 

  21. Henderson LW (1972) Rationale and evidence for the middle molecule in uremic man. Proc Workshop on Dialysis and Transplantation. Seattle, pp 69–75

  22. Hjelm M, Udén AM, Endstedt L (1976) The content of erythrocyte 2,3 diphosphoglycerate and adenosine-5-triphosphate in myelomatosis and leukaemia. Scand J Haematol 16: 48

    Google Scholar 

  23. Holstein-Ratlow NH, Hansen OP, Leyssac PP, Svendsen UG (1981) Renal plasma clearance of Lithium in myelomatosis (submitted for publication)

  24. Innes J, Newall J (1961) Myelomatosis. Lancet I: 239

    Google Scholar 

  25. Kampmann JP, Siersbaek-Nielsen K, Kristensen M, Hansen JM (1971) Aldersbetingede variationer i urinkreatinin og endogen kreatininclearance. Ugeskr Laeg 133: 2369

    Google Scholar 

  26. Kurnick JE, Ward HP, Pickett JC (1972) Mechanisms of the anaemia of chronic disorders. Arch Intern Med 130: 323

    Google Scholar 

  27. Kyle RA (1975) Multiple myeloma. Mayo Clin Proc 50: 29

    Google Scholar 

  28. Kyle RA, Elveback LR (1976) Management and prognosis of multiple myeloma. Mayo Clin Proc 51: 751

    Google Scholar 

  29. MacMahon HE, Magnus-Levy A (1936) Renal lesions in experimental Bence-Jones proteinuria. Am J Pathol 12: 763

    Google Scholar 

  30. Magnus-Levy A (1934) Multiple myelome: VII. Euglobulinämie. Zur Klinik und Pathologie. Amyloidosis. Z Klin Med 126: 62

    Google Scholar 

  31. Mandema E (1956) Over het multipel myeloom solitaire plasmocytoom en de macroglobulinaemie. Thesis. Rijksuniversiteit te Groningen, pp 109–159

  32. Martin K, Hruska KA, Greenwalt A, Klahr S, Slatopolski E (1976) Selective uptake of intact parathyroid hormone by the liver. Differences between hepatic and renal uptake. J Clin Invest 58: 781

    Google Scholar 

  33. Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E (1977) The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest 60: 808

    Google Scholar 

  34. Medical Research Council's working Party for Therapeutic Trials in Leucaemia (1973) Report on the first myelomatosis trial. Br J Haematol 24: 123

    Google Scholar 

  35. Mellstedt H, Björkholm M, Holm G (1977) Intermittent melphalan and prednisolone therapy in plasma cell myeloma. Acta Med Scand 202: 5

    Google Scholar 

  36. Myhre JR, Brodwall EK (1957) Kidney function studies in myelomatosis. Scand J Clin Lab Invest 9: 80

    Google Scholar 

  37. Preuss HG, Weiss FR, Immarino RM, Hammarck WJ, Murdaugh HV Jr (1974) Effects on rat kidney slice function in vitro of proteins from the urine of patients with myelomatosis and nephrosis. Clin Sci Mol Med 46: 283

    Google Scholar 

  38. Schubert GE, Veigel J, Lennert K (1972) Structure and function of the kidney in multiple myeloma. Virchows Arch [Pathol Anat] 355: 135

    Google Scholar 

  39. Southeastern Cancer Study Group (1975) Treatment of myeloma. Comparison of melphalan, chlorambucil and azathioprine. Arch Intern Med 135: 157

    Google Scholar 

  40. Weeke B (1973) Rocket immunelectropheresis. Scand J Immunol [Suppl 1] 2: 37

    Google Scholar 

  41. Welt LG, Black HR, Krueger KK (1970) Symposium on uremic toxins. Arch Intern Med 126: 773

    Google Scholar 

  42. Wohlmere RD, Strober W, Waldmann TA (1967) The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 126: 207

    Google Scholar 

  43. Woodruff RK, Wadsworth J, Malpas JS, Tobias JS (1979) Clinical staging in multiple myeloma. Br J Haematol 42: 199

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department C, Bispebjerg University Hospital, Denmark

    O. Paaske Hansen & Aage Drivsholm

  2. Department of Medicine, Division of Haematology, Hvidovre University Hospital, Copenhagen, Denmark

    O. Paaske Hansen & Aage Drivsholm

Authors
  1. O. Paaske Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aage Drivsholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by grants from the Danish Medical Research Council

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paaske Hansen, O., Drivsholm, A. Renal plasma clearance: A valuable marker in myelomatosis. Blut 45, 1–11 (1982). https://doi.org/10.1007/BF00320493

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00320493

Key words

Search

Navigation